GLSI logo

Greenwich LifeSciences, Inc.

GLSI
Healthcare|Biotechnology|US
$15.17
+0.52 (+3.55%)
DCF Value
$0.13
Tangible Book / Share
$0.21
Cash / Share
$0.61

About

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stock Price

+84.5%(1Y)
1M
+0.2%
3M
+5.6%
6M
-33.6%
YTD
-27.8%
1Y
+75.8%
3Y
+49.5%
5Y
-60.2%

Pipeline Summary

1 total trials
0
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 1

Active Trials (1)

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916Breast Cancer
Phase 3Recruiting
Enrollment: 2,250 participants

Key Facts

Market Cap$222.7M
Employees4 (+0% YoY)
CEOSnehal S. Patel
IPO DateSep 25, 2020
Beta1.55
52-Week Range$7.78 – $34.1
Avg Volume140,022
ExchangeNASDAQ
Websitegreenwichlifesciences.com

Ownership

Float52.1%
Shares Outstanding14.7M

Recent Insider Trades

Patel SnehalBUY
Jul 29, 2026700 shares @ $13.10
Patel SnehalBUY
Jul 28, 20261,500 shares @ $13.59
Patel SnehalBUY
Jul 27, 20261,500 shares @ $13.62
Patel SnehalBUY
Jul 24, 20261,100 shares @ $12.88
Patel SnehalBUY
Jul 23, 20262,500 shares @ $13.14

Peers

AGENAgenus Inc.
$322.9M
ATOSAtossa Therapeutics, Inc.
$21.2M
CGTXCognition Therapeutics, Inc.
$65.3M
HURATuHURA Biosciences, Inc.
$103.9M
IMMXImmix Biopharma, Inc.
$668.2M
IRDOpus Genetics, Inc.
$347.8M
ONCYOncolytics Biotech Inc.
$44.1M
SEERSeer, Inc.
$90.3M

Recent News

Greenwich LifeSciences (NASDAQ:GLSI) Stock Falls 2.1% – Time to Sell?
Oct 4, 2026 · defenseworld.net
20 stocks likely to lose money even if the bull market continues
Aug 27, 2026 · marketwatch.com
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Aug 10, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:11 AM